The likelihood of chemotherapy being cost-effective for patients with metastatic prostate cancer differs across racial subgroups. This uncertainty presents challenges for managed-care decision makers.
Michael Grabner, PhD
Advertisement
Articles by Michael Grabner, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Preparing Practices for the Next Era of Hepatitis B Care
2
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
5